Intravenous infusion of dihydroginsenoside Rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-xL

Masahiro Sakanaka, Pengxiang Zhu, Bo Zhang, Tong Chun Wen, Fang Cao, Yong Jie Ma, Keiichi Samukawa, Noriaki Mitsuda, Junya Tanaka, Makoto Kuramoto, Hidemitsu Uno, Ryuji Hata

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Red ginseng root (Panax Ginseng CA Meyer) has been used clinically by many Asian people for thousands of years without any detrimental effects. One of the major components of Red ginseng root is ginsenoside Rb1 (gRb1). Previously, we showed that intravenous infusion of gRb1 ameliorated ischemic brain damage through upregulation of an anti-apoptotic factor, Bcl-xL and that topical application of gRb1 to burn wound lesion facilitated wound healing through upregulation of vascular endothelial growth factor (VEGF). In the present study, we produced dihydroginsenoside Rb1 (dgRb1), a stable chemical derivative of gRb1, and showed that intravenous infusion of dgRb1 improved spinal cord injury (SCI) as well as ischemic brain damage. As we expected, the effective dose of dgRb1 was ten times lower than that of gRb1. Intravenous infusion of dgRb1 at this effective dose did not affect brain temperature, blood pressure or cerebral blood flow, suggesting that dgRb1 rescued damaged neurons without affecting systemic parameters. In subsequent in vitro studies that focused on dgRb1-induced expression of gene products responsible for neuronal death or survival, we showed that dgRb1 could upregulate the expression of not only Bcl-xL, but also a potent angiogenic and neurotrophic factor, VEGF. We also showed that dgRb1-induced expression of bcl-xL and VEGF mRNA was HRE (hypoxia response element) and STRE (signal transducers and activators of transcription 5 (Stat5) response element) dependent, respectively.

Original languageEnglish
Pages (from-to)1037-1054
Number of pages18
JournalJournal of Neurotrauma
Volume24
Issue number6
DOIs
Publication statusPublished - 01-06-2007

Fingerprint

Spinal Cord Injuries
Intravenous Infusions
Vascular Endothelial Growth Factor A
Up-Regulation
Brain
Panax
Response Elements
Cerebrovascular Circulation
STAT5 Transcription Factor
dihydroginsenoside Rb1
Angiogenesis Inducing Agents
Nerve Growth Factors
Wound Healing
ginsenoside Rb1
Blood Pressure
Gene Expression
Neurons
Messenger RNA
Temperature
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Sakanaka, Masahiro ; Zhu, Pengxiang ; Zhang, Bo ; Wen, Tong Chun ; Cao, Fang ; Ma, Yong Jie ; Samukawa, Keiichi ; Mitsuda, Noriaki ; Tanaka, Junya ; Kuramoto, Makoto ; Uno, Hidemitsu ; Hata, Ryuji. / Intravenous infusion of dihydroginsenoside Rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-xL. In: Journal of Neurotrauma. 2007 ; Vol. 24, No. 6. pp. 1037-1054.
@article{cdba2750a8624f38ade078f011b149d5,
title = "Intravenous infusion of dihydroginsenoside Rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-xL",
abstract = "Red ginseng root (Panax Ginseng CA Meyer) has been used clinically by many Asian people for thousands of years without any detrimental effects. One of the major components of Red ginseng root is ginsenoside Rb1 (gRb1). Previously, we showed that intravenous infusion of gRb1 ameliorated ischemic brain damage through upregulation of an anti-apoptotic factor, Bcl-xL and that topical application of gRb1 to burn wound lesion facilitated wound healing through upregulation of vascular endothelial growth factor (VEGF). In the present study, we produced dihydroginsenoside Rb1 (dgRb1), a stable chemical derivative of gRb1, and showed that intravenous infusion of dgRb1 improved spinal cord injury (SCI) as well as ischemic brain damage. As we expected, the effective dose of dgRb1 was ten times lower than that of gRb1. Intravenous infusion of dgRb1 at this effective dose did not affect brain temperature, blood pressure or cerebral blood flow, suggesting that dgRb1 rescued damaged neurons without affecting systemic parameters. In subsequent in vitro studies that focused on dgRb1-induced expression of gene products responsible for neuronal death or survival, we showed that dgRb1 could upregulate the expression of not only Bcl-xL, but also a potent angiogenic and neurotrophic factor, VEGF. We also showed that dgRb1-induced expression of bcl-xL and VEGF mRNA was HRE (hypoxia response element) and STRE (signal transducers and activators of transcription 5 (Stat5) response element) dependent, respectively.",
author = "Masahiro Sakanaka and Pengxiang Zhu and Bo Zhang and Wen, {Tong Chun} and Fang Cao and Ma, {Yong Jie} and Keiichi Samukawa and Noriaki Mitsuda and Junya Tanaka and Makoto Kuramoto and Hidemitsu Uno and Ryuji Hata",
year = "2007",
month = "6",
day = "1",
doi = "10.1089/neu.2006.0182",
language = "English",
volume = "24",
pages = "1037--1054",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

Sakanaka, M, Zhu, P, Zhang, B, Wen, TC, Cao, F, Ma, YJ, Samukawa, K, Mitsuda, N, Tanaka, J, Kuramoto, M, Uno, H & Hata, R 2007, 'Intravenous infusion of dihydroginsenoside Rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-xL', Journal of Neurotrauma, vol. 24, no. 6, pp. 1037-1054. https://doi.org/10.1089/neu.2006.0182

Intravenous infusion of dihydroginsenoside Rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-xL. / Sakanaka, Masahiro; Zhu, Pengxiang; Zhang, Bo; Wen, Tong Chun; Cao, Fang; Ma, Yong Jie; Samukawa, Keiichi; Mitsuda, Noriaki; Tanaka, Junya; Kuramoto, Makoto; Uno, Hidemitsu; Hata, Ryuji.

In: Journal of Neurotrauma, Vol. 24, No. 6, 01.06.2007, p. 1037-1054.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravenous infusion of dihydroginsenoside Rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-xL

AU - Sakanaka, Masahiro

AU - Zhu, Pengxiang

AU - Zhang, Bo

AU - Wen, Tong Chun

AU - Cao, Fang

AU - Ma, Yong Jie

AU - Samukawa, Keiichi

AU - Mitsuda, Noriaki

AU - Tanaka, Junya

AU - Kuramoto, Makoto

AU - Uno, Hidemitsu

AU - Hata, Ryuji

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Red ginseng root (Panax Ginseng CA Meyer) has been used clinically by many Asian people for thousands of years without any detrimental effects. One of the major components of Red ginseng root is ginsenoside Rb1 (gRb1). Previously, we showed that intravenous infusion of gRb1 ameliorated ischemic brain damage through upregulation of an anti-apoptotic factor, Bcl-xL and that topical application of gRb1 to burn wound lesion facilitated wound healing through upregulation of vascular endothelial growth factor (VEGF). In the present study, we produced dihydroginsenoside Rb1 (dgRb1), a stable chemical derivative of gRb1, and showed that intravenous infusion of dgRb1 improved spinal cord injury (SCI) as well as ischemic brain damage. As we expected, the effective dose of dgRb1 was ten times lower than that of gRb1. Intravenous infusion of dgRb1 at this effective dose did not affect brain temperature, blood pressure or cerebral blood flow, suggesting that dgRb1 rescued damaged neurons without affecting systemic parameters. In subsequent in vitro studies that focused on dgRb1-induced expression of gene products responsible for neuronal death or survival, we showed that dgRb1 could upregulate the expression of not only Bcl-xL, but also a potent angiogenic and neurotrophic factor, VEGF. We also showed that dgRb1-induced expression of bcl-xL and VEGF mRNA was HRE (hypoxia response element) and STRE (signal transducers and activators of transcription 5 (Stat5) response element) dependent, respectively.

AB - Red ginseng root (Panax Ginseng CA Meyer) has been used clinically by many Asian people for thousands of years without any detrimental effects. One of the major components of Red ginseng root is ginsenoside Rb1 (gRb1). Previously, we showed that intravenous infusion of gRb1 ameliorated ischemic brain damage through upregulation of an anti-apoptotic factor, Bcl-xL and that topical application of gRb1 to burn wound lesion facilitated wound healing through upregulation of vascular endothelial growth factor (VEGF). In the present study, we produced dihydroginsenoside Rb1 (dgRb1), a stable chemical derivative of gRb1, and showed that intravenous infusion of dgRb1 improved spinal cord injury (SCI) as well as ischemic brain damage. As we expected, the effective dose of dgRb1 was ten times lower than that of gRb1. Intravenous infusion of dgRb1 at this effective dose did not affect brain temperature, blood pressure or cerebral blood flow, suggesting that dgRb1 rescued damaged neurons without affecting systemic parameters. In subsequent in vitro studies that focused on dgRb1-induced expression of gene products responsible for neuronal death or survival, we showed that dgRb1 could upregulate the expression of not only Bcl-xL, but also a potent angiogenic and neurotrophic factor, VEGF. We also showed that dgRb1-induced expression of bcl-xL and VEGF mRNA was HRE (hypoxia response element) and STRE (signal transducers and activators of transcription 5 (Stat5) response element) dependent, respectively.

UR - http://www.scopus.com/inward/record.url?scp=34347339390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347339390&partnerID=8YFLogxK

U2 - 10.1089/neu.2006.0182

DO - 10.1089/neu.2006.0182

M3 - Article

C2 - 17600519

AN - SCOPUS:34347339390

VL - 24

SP - 1037

EP - 1054

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 6

ER -